Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 10/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17945140 | 0.94 | CASR (0.44) | CASR | |
| SCHEMBL16540583 | 0.92 | CASR (0.44) | CASRPPARGPFKFB3LMNATP53 | |
| SCHEMBL16548315 | 0.92 | CASR (0.44) | CASRPPARGPFKFB3LMNATP53 | |
| SCHEMBL16548153 | 0.92 | CASR (0.54) | CASRPPARG | |
| Hydrochloric Acid SCHEMBL17939907 | 0.92 | CASR (0.43) | CASRPPARGPFKFB3LMNATP53 | |
| Hydrochloric Acid SCHEMBL17939905 | 0.92 | CASR (0.43) | CASRPPARGPFKFB3LMNATP53 | |
| SCHEMBL17945905 | 0.91 | CASR (0.43) | CASRPFKFB3 | |
| SCHEMBL16548132 | 0.91 | CASR (0.46) | CASRPPARGLMNATP53 | |
| SCHEMBL16548098 | 0.91 | CASR (0.46) | CASRPPARGPFKFB3LMNATP53 | |
| SCHEMBL17939900 | 0.87 | CASR (0.41) | CASRPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493396-B2 | Substituted naphthalene compounds as calcium sensing receptor modulators | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-11-15 | — | — | US | disclosed |
| US-9493396-B2 | Substituted naphthalene compounds as calcium sensing receptor modulators | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20160214924-A1 | SUBSTITUTED NAPHTHALENE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-07-28 | — | — | US | disclosed |
| US-20160214924-A1 | SUBSTITUTED NAPHTHALENE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-07-28 | — | — | US | disclosed |
| WO-2015028938-A1 | SUBSTITUTED NAPHTHALENE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2015-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214924-A1 | SUBSTITUTED NAPHTHALENE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | CASR, RYR2, RYR1 | CASR 1/4885PPARG 876/4885PFKFB3 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.